2'OMe Modification of Anti-miRNA-21 Oligonucleotide–Peptide Conjugate Improves Its Hybridization Properties and Catalytic Activity


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

Nowadays, application of miRNases—artificial ribonucleases aimed at degradation of noncoding RNAs, in particular, miRNAs—represents one of the novel experimental approaches to inhibit tumorigenesis. miRNases integrate in their structure an addressing oligonucleotide, which provides specific binding with miRNA target, and a catalytic group, which promotes cleavage of the RNA substrate. Introduction of chemical modifications to the oligonucleotide domain of miRNases in the region that is complementary to miRNA may significantly increase the hybridization properties and nuclease resistance of this type of compound. However, the influence of such structural changes to the ribonuclease activity of miRNases remains unclear. In this work, to investigate the effect of 2'OMe modifications on the activity of miRNases, we synthesized two types of anti-miRNA-21 conjugates of the peptide [(ArgLeu)2Gly]2 and hairpin oligonucleotides in which 14-mer binding region to the miRNA target was fully or partially modified. It is shown that the introduction of 2'OMe modifications promotes a considerable increase in the affinity of miRNases to miRNA-21 but does not change significantly their nuclease resistance. Full modification of conjugates in the region that is complementary to miRNA negatively affects their ribonuclease activity, whereas partial introduction of 2'OMe nucleotides considerably enhances the cleavage activity of miRNases, which leads to a substantial decrease in the proliferation rate and migration potential of tumor cells, which are determined by the miRNA-21 expression.

Keywords: oligonucleotide–peptide conjugates, oncogenic miRNA, miRNA-21, 2'OMe modification, human epidermoid carcinoma KB-8-5.

Sobre autores

S. Miroshnichenko

Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences

Email: patutina@niboch.nsc.ru
Rússia, Novosibirsk, 630090

B. Amirloo

School of Health Sciences, Faculty of Biology, Medicine, and Health, University of Manchester

Email: patutina@niboch.nsc.ru
Reino Unido da Grã-Bretanha e Irlanda do Norte, Manchester, M13 9PL

E. Bichenkova

School of Health Sciences, Faculty of Biology, Medicine, and Health, University of Manchester

Email: patutina@niboch.nsc.ru
Reino Unido da Grã-Bretanha e Irlanda do Norte, Manchester, M13 9PL

V. Vlassov

Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences

Email: patutina@niboch.nsc.ru
Rússia, Novosibirsk, 630090

M. Zenkova

Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences

Email: patutina@niboch.nsc.ru
Rússia, Novosibirsk, 630090

O. Patutina

Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences

Autor responsável pela correspondência
Email: patutina@niboch.nsc.ru
Rússia, Novosibirsk, 630090

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Pleiades Publishing, Ltd., 2019